HealthEquity, Inc. (NASDAQ:HQY) Shares Sold by Profund Advisors LLC

Profund Advisors LLC lessened its stake in HealthEquity, Inc. (NASDAQ:HQY) by 15.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,079 shares of the company’s stock after selling 733 shares during the quarter. Profund Advisors LLC’s holdings in HealthEquity were worth $352,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of HealthEquity in the 4th quarter worth $43,482,000. Hsbc Holdings PLC purchased a new stake in shares of HealthEquity in the fourth quarter valued at about $4,490,000. Parallel Advisors LLC increased its position in HealthEquity by 255.5% during the fourth quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock worth $45,000 after purchasing an additional 488 shares during the last quarter. TFO Wealth Partners LLC raised its stake in HealthEquity by 30,025.0% during the fourth quarter. TFO Wealth Partners LLC now owns 1,205 shares of the company’s stock worth $80,000 after purchasing an additional 1,201 shares during the period. Finally, Capstone Investment Advisors LLC boosted its holdings in HealthEquity by 7.0% in the 4th quarter. Capstone Investment Advisors LLC now owns 3,710 shares of the company’s stock valued at $246,000 after purchasing an additional 243 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Insider Transactions at HealthEquity

In related news, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the transaction, the insider now directly owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Frank Corvino sold 7,705 shares of HealthEquity stock in a transaction on Monday, July 8th. The shares were sold at an average price of $81.89, for a total transaction of $630,962.45. Following the completion of the sale, the director now directly owns 6,070 shares of the company’s stock, valued at approximately $497,072.30. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the transaction, the insider now directly owns 89,769 shares in the company, valued at approximately $7,168,952.34. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Robert W. Baird lifted their price target on shares of HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. Bank of America reduced their target price on HealthEquity from $105.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Wells Fargo & Company increased their price target on HealthEquity from $107.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, June 20th. JMP Securities restated a “market outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a report on Wednesday, September 4th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, HealthEquity currently has an average rating of “Moderate Buy” and a consensus price target of $103.83.

HealthEquity Price Performance

Shares of HQY opened at $78.64 on Friday. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a fifty-two week low of $61.81 and a fifty-two week high of $88.26. The company has a market cap of $6.87 billion, a P/E ratio of 85.48, a PEG ratio of 1.25 and a beta of 0.52. The firm’s 50 day moving average price is $76.16 and its 200 day moving average price is $79.27.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.